The activation of AMPK, a central sensor of cellular energy, has emerged as a therapeutic target for obesity of which is essential for the inhibition of adipocyte lipogenesis [36, 37]. This evidence concerns the gene PRKAA1 and obesity due to melanocortin 4 receptor deficiency.